Financial Shenanigans

Financial Shenanigans

Centene earns a Forensic Risk Score of 38 (Watch). The two primary concerns are (1) the largest non-GAAP-to-GAAP gap in managed care ($15.61/share in FY2025), driven by a $6.7B goodwill impairment with classic big-bath timing, and (2) volatile cash-flow presentation distorted by CMS Part D receivable timing and a $1B receivable sale in Q1 2026. The cleanest offsetting evidence: over 95% of revenue comes directly from government agencies via capitated contracts, making revenue fabrication structurally difficult. The one data point that would change the grade: if the remaining $10.8B in goodwill required further impairment testing, pushing the score toward Elevated.

The Forensic Verdict

Breeding Ground

The breeding ground risk at Centene is moderate. Governance is adequate but compensation structure creates incentive alignment concerns.

The adjusted EPS metric used for compensation creates a mild incentive to classify charges as "non-recurring." FY2025's $7.2B in impairments were excluded from adjusted EPS, and the CEO's compensation structure is heavily weighted toward stock awards ($15.5M of $19.5M). That said, managed care executives industry-wide use adjusted EPS as a primary metric, and the specific adjustments (goodwill impairment, divestiture-related) are well-disclosed and largely non-discretionary.

Earnings Quality

Revenue quality is structurally clean. Centene's revenue is overwhelmingly capitated premium payments from CMS and state Medicaid agencies — there is no revenue recognition judgment, no channel stuffing, no related-party sales risk. Revenue grows when membership grows, rates increase, or the PDP premium structure changes.

Big-bath concern: goodwill impairment timing. The $6.7B goodwill impairment in Q3 2025 and $513M Magellan impairment in Q4 2025 have the hallmarks of a big-bath reset. CEO Sarah London took the role in 2021; by FY2025, the accumulated write-downs ($7.2B total) effectively reset the baseline for future returns on equity and profitability metrics. The impairments were triggered by a quantitative test (stock price decline forcing carrying value above fair value), not a discretionary management decision, which limits the big-bath concern. But the timing — FY2025, the worst earnings year, when the impact on adj EPS is already excluded — is forensically convenient.

Divestiture gains are recurring "one-time" items. Centene has recognized divestiture gains in FY2022 ($269M Magellan Rx), FY2023 ($79M Magellan Specialty Health), FY2024 ($83M contingent consideration + $20M Circle Health + $17M CHS). Each was excluded from adjusted EPS, but the pattern of annual divestiture gains acting as a GAAP earnings supplement warrants monitoring.

Cash Flow Quality

The CFO-to-NI relationship is noisy but ultimately explainable:

FY2024 anomaly ($154M OCF vs. $3.3B NI): This is the most forensically suspicious year. The CMS Part D risk-sharing receivable timing — CNC paid out claims but hadn't yet collected from CMS — explains most of the gap. This is a real timing effect, not manipulation, but it makes trailing-period CFO/NI ratios unreliable.

FY2025 ($5.1B OCF vs. -$6.7B NI): Entirely explained by $7.2B in non-cash impairments. OCF quality is actually strong in FY2025.

Part D receivable sale (Q1 2026): CNC sold $1B of 2025 Part D risk-share receivables and used proceeds to repay $1B in senior notes. This is disclosed and transparent, but it shifts cash from future periods into Q1 2026's $4.4B operating cash flow. This is a C1 shenanigan (financing inflow presented as operating) in the taxonomy, though it is standard practice in PDP operations and fully disclosed.

From FY2018–2020, acquisition-adjusted FCF was dramatically lower than reported FCF, reflecting the WellCare ($17B) and other acquisitions. Since FY2023, no acquisitions have occurred, and FCF and adj-FCF converge. The acquisition era is over for now.

Metric Hygiene

The non-GAAP gap is the single biggest forensic concern in metric hygiene. FY2025 adjusted EPS of $2.08 excludes $15.61/share in adjustments — an unprecedented divergence. While each individual adjustment is defensible (goodwill impairment, amortization of acquired intangibles, divestiture items), the cumulative effect means investors relying on adjusted EPS are looking at a fundamentally different company than GAAP presents.

Amortization of acquired intangibles ($1.39/share in FY2025) is excluded from adjusted EPS every year. This is standard industry practice but represents a real economic cost — the WellCare and Magellan acquisitions cost real cash, and amortization reflects the consumption of that value. Over FY2021–2025, this exclusion alone added $6.6/share to cumulative adjusted EPS.

What to Underwrite Next

Watch these five items:

1. Remaining goodwill ($10.8B): If the stock price declines materially or Medicaid margins don't recover, another impairment test is triggered. The $10.8B remaining is still large relative to the $20B equity base.

2. Days in claims payable trend: 48 days in Q1 2026. If this declines to 44–45 days, it could signal reserve releases boosting earnings. If it rises to 50+, it signals worsening cost uncertainty.

3. Part D receivable collection: CNC expects to collect remaining 2025 CMS receivables by October 2026. Any delays would stress cash flow and potentially signal CMS payment disputes.

4. Non-GAAP gap normalization: With the $6.7B goodwill impairment behind them, the FY2026 GAAP-to-adjusted gap should shrink dramatically. If it doesn't — if new "one-time" charges emerge — that escalates the forensic score.

5. Magellan divestiture economics: The December 2025 agreement to divest remaining Magellan businesses triggered a $513M impairment. Watch the actual sale price vs. carrying value for further write-downs.

The accounting risk at Centene is a valuation haircut, not a thesis breaker. Government-sourced capitated revenue eliminates the most dangerous earnings manipulation vectors. The non-GAAP gap is enormous but driven by identifiable, non-cash items that are now largely behind the company. The residual risk is in reserve adequacy (DCP), CMS receivable timing, and the possibility that another goodwill impairment surfaces if the margin recovery stalls. Investors should demand a wider margin of safety than the managed care sector typically requires — but should not mistake a messy accounting year for a structurally compromised business.